Literature DB >> 19004949

A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection.

Lars Frelin1, Therese Wahlström, Amy E Tucker, Joyce Jones, Janice Hughes, Byung O Lee, Jean-Noel Billaud, Cory Peters, David Whitacre, Darrell Peterson, David R Milich.   

Abstract

Hepatitis B virus (HBV) expresses two structural forms of the nucleoprotein, the intracellular nucleocapsid (hepatitis core antigen [HBcAg]) and the secreted nonparticulate form (hepatitis e antigen [HBeAg]). The aim of this study was to evaluate the ability of HBcAg- and HBeAg-specific genetic immunogens to induce HBc/HBeAg-specific CD4(+)/CD8(+) T-cell immune responses and the potential to induce liver injury in HBV-transgenic (Tg) mice. Both the HBcAg- and HBeAg-specific plasmids primed comparable immune responses. Both CD4(+) and CD8(+) T cells were important for priming/effector functions of HBc/HBeAg-specific cytotoxic T-lymphocyte (CTL) responses. However, a unique two-step immunization protocol was necessary to elicit maximal CTL priming. Genetic vaccination did not prime CTLs in HBe- or HBc/HBeAg-dbl-Tg mice but elicited a weak CTL response in HBcAg-Tg mice. When HBc/HBeAg-specific CTLs were adoptively transferred into HBc-, HBe-, and HBc/HBeAg-dbl-Tg mice, the durations of the liver injury and inflammation were significantly greater in HBeAg-Tg recipient mice than in HBcAg-Tg mice. Importantly, liver injury in HBc/HBeAg-dbl-Tg mice was similar to the injury observed in HBeAg-Tg mice. Loss of HBeAg synthesis commonly occurs during chronic HBV infection; however, the mechanism of selection of HBeAg-negative variants is unknown. The finding that hepatocytes expressing wild-type HBV (containing both HBcAg and HBeAg) are more susceptible to CTL-mediated clearance than hepatocytes expressing only HBcAg suggest that the HBeAg-negative variant may have a selective advantage over wild-type HBV within the livers of patients with chronic infection during an immune response and may represent a CTL escape mutant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004949      PMCID: PMC2620889          DOI: 10.1128/JVI.01902-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.

Authors:  A Kuhöber; H P Pudollek; K Reifenberg; F V Chisari; H J Schlicht; J Reimann; R Schirmbeck
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

2.  Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members.

Authors:  U S Akarca; S Greene; A S Lok
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

3.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

4.  Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens.

Authors:  K Townsend; M Sällberg; J O'Dea; T Banks; D Driver; S Sauter; S M Chang; D J Jolly; S J Mento; D R Milich; W T Lee
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes.

Authors:  A Kuhröber; J Wild; H P Pudollek; F V Chisari; J Reimann
Journal:  Int Immunol       Date:  1997-08       Impact factor: 4.823

6.  Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation.

Authors:  P W Angus; S A Locarnini; G W McCaughan; R M Jones; J S McMillan; D S Bowden
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

7.  Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice.

Authors:  L G Guidotti; V Martinez; Y T Loh; C E Rogler; F V Chisari
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 8.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

9.  The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; C Pasquinelli; J M Shoenberger; C E Rogler; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

Authors:  B Rehermann; P Fowler; J Sidney; J Person; A Redeker; M Brown; B Moss; A Sette; F V Chisari
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Animal models and the molecular biology of hepadnavirus infection.

Authors:  William S Mason
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  A high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infection.

Authors:  Bernadette Schmid; Christine Rösler; Michael Nassal
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Authors:  Ruy M Ribeiro; Georgios Germanidis; Kimberly A Powers; Bertrand Pellegrin; Paul Nikolaidis; Alan S Perelson; Jean-Michel Pawlotsky
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

4.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 5.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

6.  Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells.

Authors:  Yasuteru Kondo; Osamu Kimura; Yasuhito Tanaka; Masashi Ninomiya; Tomoaki Iwata; Takayuki Kogure; Jun Inoue; Masaya Sugiyama; Tatsuki Morosawa; Yasuyuki Fujisaka; Tooru Shimosegawa
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

Review 7.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 8.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

9.  The L60V variation in hepatitis B virus core protein elicits new epitope-specific cytotoxic T lymphocytes and enhances viral replication.

Authors:  Yu Zhang; Yulin Ren; Yan Wu; Bao Zhao; Lipeng Qiu; Xiaodong Li; Dongping Xu; Jun Liu; George F Gao; Songdong Meng
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.